AMGN

SEC source: 0001127602-24-009245 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,597

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 148 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-009246 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,863

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 137 RSUs which will vest on 5/5/2024; 263 RSUs which will vest in one installment of 129 on 4/30/2024 and one installment of 134 on 4/30/2025; 866 RSUs which will vest in installments of 285 on 5/2/2024, 286 on 5/2/2025, and 295 on 5/2/2026; and 1,101 RSUs which will vest in two installments of 363 each on 5/2/2025 and 5/2/2026, and 375 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 122 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-009247 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,653

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 each on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 715 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-009249 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,125

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,151 RSUs which will vest on 5/5/2024; 2,656 RSUs which will vest in installments of 1,308 on 4/30/2024 and 1,348 on 4/30/2025; 3,637 RSUs which will vest in two installments of 1,200 each on 5/2/2024 and 5/2/2025, and one installment of 1,237 on 5/2/2026; and 3,559 RSUs which will vest in two installments of 1,174 each on 5/2/2025 and 5/2/2026, and one installment of 1,211 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 670 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-004620 · form4.xml · nonDerivative · entry 2

Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,393

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; and 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

SEC source: 0001127602-24-004620 · form4.xml · nonDerivative · entry 1

Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,587

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028, respectively.

SEC source: 0001127602-23-028779 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,874

F1 · price: The price reported is an average price. The prices ranged from $273.00 to $273.17 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-028437 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,164

F1 · kind: The transaction reported involved gifts by the reporting person of shares of the Company's common stock to six charitable organizations.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 each on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 633 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-027292 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,078

F1 · balance_after: The price reported is an average price. The prices ranged from $272.79 to $272.96 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments each of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 579 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026975 · form4.xml · nonDerivative · entry 2

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,367

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 101 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026975 · form4.xml · nonDerivative · entry 1

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,550

SEC source: 0001127602-23-026976 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,970

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 649 RSUs which will vest in two installments of 214 each on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026977 · form4.xml · nonDerivative · entry 2

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,323

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and one installment of 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 130 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026977 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,467

SEC source: 0001127602-23-026978 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,533

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 137 RSUs which will vest on 5/5/2024; 263 RSUs which will vest in one installment of 129 on 4/30/2024 and one installment of 134 on 4/30/2025; 866 RSUs which will vest in installments of 285 on 5/2/2024, 286 on 5/2/2025, and 295 on 5/2/2026; 1,101 RSUs which will vest in two installments of 363 each on 5/2/2025 and 5/2/2026, and 375 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 103 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026972 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,301.2161

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSU's may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 54 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026973 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,575.4958

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 774 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026974 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,813.1172

F1 · balance_after: The Restricted Stock Units (RSUs) were granted, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 87 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026804 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,078

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments each of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 579 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-026805 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,820

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,151 RSUs which will vest on 5/5/2024; 2,237 RSUs which will vest in installments of 1,102 on 4/30/2024 and 1,135 on 4/30/2025; 3,897 RSUs which will vest in two installments each of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026 and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 591 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-23-022410 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,308

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-022309 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,024.3505

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSU's may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 18 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-022310 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,525.2516

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-022311 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,132.0458

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 627 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-021594 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,095

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 2,780 RSUs which will vest on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 304 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016631 · form4.xml · nonDerivative · entry 1

Austin Wanda M · CIK 0001690882 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,825

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

SEC source: 0001127602-23-016632 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,899.7339

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSU's may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 18 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016633 · form4.xml · nonDerivative · entry 1

Druker Brian · CIK 0001740205 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,688

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 406 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016634 · form4.xml · nonDerivative · entry 1

ECKERT ROBERT · CIK 0001194256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,465

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 2,350 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016635 · form4.xml · nonDerivative · entry 1

Garland Greg C. · CIK 0001503107 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,655

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested imediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-23-016636 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,978.6716

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 627 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016637 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,400.635

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016639 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,208.9807

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 987 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016638 · form4.xml · nonDerivative · entry 1

Jacks Tyler · CIK 0001464237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,868

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Plan) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 1,752 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016640 · form4.xml · nonDerivative · entry 1

MILES AMY E · CIK 0001248617 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,115

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 76 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016641 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,682

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 3,388 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-016642 · form4.xml · nonDerivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,240

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

SEC source: 0001127602-23-015043 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 641,734

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,143 RSUs which will vest on 5/5/2024; 8.898 RSUs which will vest in installments of 4,382 on 4/30/2024 and 4,516 on 4/30/2025; 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026; and 13,486 RSUs which will vest in two installments of 4,450 on 5/2/2025 and 5/2/2026, and 4,586 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,431 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015044 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,866

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015045 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,573

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,120 RSUs which will vest on 11/1/2023; 1,122 RSUs which will vest on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 734 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015046 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,990

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,240 RSUs which will vest on 11/1/2023; 1,151 RSUs which will vest on 5/5/2024; 2,237 RSUs which will vest in installments of 1,102 on 4/30/2024 and 1,135 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026 and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,081 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-23-015047 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,224

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 144 RSUs which will vest on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 571 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015048 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,581

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 468 RSUs which will vest on 11/5/2023; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and one installment of 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 128 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015049 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,966

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 58 RSUs which will vest on 5/5/2024; 974 RSUs which will vest in installments of 479 on 11/2/2023 and 495 on 11/2/2024; 201 RSUs which will vest in installments of 99 on 4/30/2024 and 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026; and 423 RSUs which will vest in installments of 139 on 5/2/2025, 140 on 5/2/2026 and 144 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 123 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015050 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,553

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 58 RSUs which will vest on 5/5/2024; 974 RSUs which will vest in installments of 479 on 11/2/2023 and 495 on 11/2/2024; 201 RSUs which will vest in installments of 99 on 4/30/2024 and 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.; and 1,101 RSUs which will vest in two installments of 363 on 5/2/2025 and 5/2/2026, and 375 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015051 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,114

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 418 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015052 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,582

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,151 RSUs which will vest on 5/5/2024; 2,656 RSUs which will vest in installments of 1,308 on 4/30/2024 and 1,348 on 4/30/2025; 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026; and 3,559 RSUs which will vest in two installments of 1,174 on 5/2/2025 and 5/2/2026, and 1,211 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 405 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014605 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 643,817

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 8,164 RSUs which will vest in installments of 4,021 on 5/5/2023 and 4,143 on 5/5/2024; 8.898 RSUs which will vest in installments of 4,382 on 4/30/2024 and 4,516 on 4/30/2025; 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026; and 13,486 RSUs which will vest in two installments of 4,450 on 5/2/2025 and 5/2/2026, and 4,586 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,818 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014607 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,165

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and 1,291 on 4/30/2025; 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026; and 3,390 RSUs which will vest in installments of 1,118 on 5/2/2025, 1,119 on 5/2/2026 and 1,153 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014608 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,489

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 549 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.